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Abstract  
Recent clinical and preclinical studies have shown that different hyperkinetic disorders such as 
Huntington's disease, dystonia and L-DOPA-induced dyskinesia in Parkinson’s disease are all 
characterized by loss of the ability to reverse synaptic plasticity and an associated increase in 
excitability of excitatory neuronal inputs to a range of cortical and subcortical brain areas. 
Moreover, these changes have been detected in patients either via direct recordings from implanted 
deep brain electrodes, or non-invasively using techniques of transcranial magnetic stimulation. Here 
we discuss the mechanisms underlying the loss of bidirectional plasticity and the possibility that 
future interventions could be devised to reverse these changes in patients with hyperkinetic 
movement disorders.  
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Introduction   
The ability to adjust movements to fit task requirements employs plastic mechanisms operating at 
the level of cortex and striatum1. These mechanisms regulate the excitability of output structures 
and limit excessive neuronal activity without compromising the stability and integrity of the 
underlying circuits that drive behavior. This ability is often referred to as “homeostatic” plasticity, a 
mechanism that allows neurons to sense their functional state and to adjust their properties to 
maintain stable function2.  
Physiological adaptations related to motor learning require neural networks able to detect 
correlations between environmental events and to store this information as changes in synaptic 
strength. Classical examples of brain activity-dependent adaptations are long-term potentiation 
(LTP) and long-term depression (LTD)3. However, excessive expression of these forms of plasticity 
can be detrimental for behavior and motor activity. For example, failure of homeostatic mechanisms 
to control expression of LTP in the basal ganglia could result in abnormal potentiation of all 
synaptic inputs leading to excessive excitability as well as abnormal changes in neuronal 
morphology and synapse number. In the present perspective, we propose that the loss of synaptic 
down-scaling would lead to a loss of control of LTP in the basal ganglia, as well as in the cortex, 
and to hyperkinetic motor manifestations, such as those observed in Huntington’s disease (HD), 
dystonia, and L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID) in Parkinson’s 
disease (PD). 
HD, dystonia, and LID can all be classified as hyperkinetic disorders although they differ in their 
mixture of dyskinetic, choreic, and dystonic movements4. Recent advances in genetic, molecular, 
and imaging studies have allowed a better understanding of the similarities and differences between 
them. It has been suggested that LID, dystonia, and HD share several molecular and synaptic 
abnormalities which seems surprising since distinct neuronal subtypes are affected by the different 
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pathologies. Yet, as we show below, all can lead to changes in control of synaptic plasticity.  
HD is a progressive neurodegenerative disorder, causing movement, mood and cognition 
alterations, which profoundly impairs processing of corticostriatal information5. While late stage 
pathology in HD involves cell death, the appearance of early motor manifestations is associated 
with subtle functional alterations in the excitatory synaptic activity and in the formation of aberrant 
cortical and subcortical plasticity6. In the early stage of HD, neuronal death is rare. Similarly, most 
primary forms of dystonia do not cause neurodegeneration either early or late in the disease; instead 
they are associated with an imbalance of transmitters and other biochemical abnormalities7,8. From 
the pathophysiological point of view, the pathogenesis of LID in PD is more complex. The loss of 
the majority of nigral dopaminergic neurons, leading to a dramatic striatal dopamine (DA) 
denervation, is an essential precondition for the expression of LID9,10. However, hyperkinesias only 
occur if associated with subtle alterations of the dendritic spines of cortical and striatal neurons11,12. 
In the past, the difficulties in modeling pathology together with the complexity of the corticostriatal 
network allowed only a partial understanding of the mechanisms driving these specific hyperkinetic 
conditions. Recently, advances in building appropriate experimental models and new experimental 
tools such as optogenetics and novel techniques of functional imaging and clinical neurophysiology 
have permitted a more accurate analysis of the circuit-specific deficits. This has allowed a 
redefinition of the models of neurologic hyperkinetic disorders.   
 
Cortical and striatal pathological synaptic potentiation of excitatory transmission in 
experimental models of Huntington’s disease 
HD is a genetic neurodegenerative condition causing disorders of movement, mood and cognition 
that is induced by a polyglutamine expansion in the huntingtin (Htt) protein6. Genetic mouse 
models of HD, in association with improved imaging techniques both in HD patients and subjects at 
risk of the disease, have contributed to a better knowledge of the cellular and molecular 
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mechanisms underlying the pathogenesis of HD. The neurodegenerative process starts earlier in the 
striatum than in other brain areas, and abnormal activity of glutamatergic corticostriatal synapses 
contributes to an imbalance in survival- versus death-signaling pathways within the striatum5,13. 
Striatal projection neurons (SPNs) of the indirect pathway seem more vulnerable than those of the 
direct pathway and their dysfunction contributes to motor symptoms during early stages of the 
disease14. Since the striatum is the primary location of the neurodegenerative process, it has been 
hypothesized that down-scaling of the plasticity of striatal glutamatergic synapses on striatal neurons 
is impaired, and that this leads to early cognitive and motor symptoms. In support of this hypothesis, 
alterations in the induction and reversal of synaptic plasticity have been demonstrated in a genetic 
(R6/2 mice) model of the disease. Striatal SPNs in this model have been shown to express normal 
LTP, but to be unable to depotentiate their synapses after a low-frequency stimulation (LFS) protocol 
(Figure 1A)15. The inability of SPNs to reverse synaptic strength to pre-LTP levels disrupts 
homeostatic regulatory processes that destabilize neuronal circuits during information storage and 
could contribute to the impaired behavioral flexibility described in early-stage HD patients15.  
It has been proposed that reduced brain-derived neurotrophic factor (BDNF) transcription, transport 
and signaling contribute to striatal neuronal dysfunction and degeneration in HD6. However, this 
view has recently been challenged, since in mouse models of early symptomatic HD, BDNF 
delivery to the striatum and its activation of tyrosine-related kinase B (TrkB) receptors were found 
to be normal, while TrkB receptor activation resulted in an aberrant postsynaptic control of 
induction of potentiation at corticostriatal synapses16. It seems likely that the consequence of the 
expression of mutant Htt is a change in striatal excitatory synaptic activity, triggered by a decrease 
of glutamate uptake and by increased signaling at NMDA receptors17.  
Striatal DA signaling is also altered in HD and progresses through the course of the disease18. 
Alterations of the A2A adenosine receptors (A2AR) mirror changes of the DA system since both 
DA and A2AR converge on the regulation of the cAMP/PKA/DARPP-32 pathway that, in turn, 
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regulates the efficacy of glutamatergic transmission and striatal plasticity (Figure 2)19,20. Up-
regulation of PKA activity and increased function of A2AR are also seen in HD patients20-23. 
Accordingly, genetic inactivation or pharmacological manipulation of A2AR prevent or reverse 
working memory deficits in early HD, respectively24.   
Based on clinical and experimental findings, it has been hypothesized that some of the behavioral 
alterations in HD, including reduced behavioral flexibility, may be caused by altered DA 
modulatory function25. Interestingly, aberrant synaptic plasticity and dopaminergic dysfunction has 
been shown not only in the striatum, but also in the cortex of a mouse model of HD26.  
Altered spine and synaptic plasticity could underlie the motor as well as cognitive symptoms in HD. 
Recently, the kinetics of spine alterations and plasticity in HD has been investigated using long-
term two-photon imaging to track individual dendritic spines in the R6/2 genetic model27. In R6/2 
mice the probability that newly formed spines are stabilized and transformed into persistent spines 
was greatly reduced compared to controls, and in R6/2 mice, aggregates of mutant htt were 
localized in dendritic spines. The evidence that alterations in dendritic spine dynamics, survival, and 
density in R6/2 mice appear before the onset of motor symptoms indicates that decreased stability 
of the cortical synaptic circuitry underlies the early symptoms in HD. 
Experimental models of HD suggest that striatal grafts might rescue motor deficits and learning of 
complex motor skills in experimental models of HD. Embryonic striatal grafts create functional 
connections with the host striatal circuitry, and restore synaptic transmission facilitating the 
recovery of bidirectional synaptic plasticity28.  
 
Aberrant synaptic plasticity in experimental models of dystonia  
Dystonia comprises a heterogeneous group of “hyperkinetic” movement disorders characterized by 
sustained muscle contractions, causing twisting repetitive movements and abnormal postures. 
Dystonia can be classified by age at onset, by distribution (focal, segmental, generalized, or 
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hemidystonia) or by aetiology (isolated or combined)29. Gross and light microscopic examination 
fail to reveal relevant neuropathological changes in the brain8, consisting with the idea that the 
pathophysiology of dystonia is determined by abnormalities in neural processing and synaptic 
plasticity. The discovery of various genes implicated in dystonia as well as the experimental use of 
new genetic models has provided information about the mechanisms of the disease30. Unfortunately, 
most of these rodent models do not exhibit overt dystonia, although they show subtle motor 
abnormalities with peculiar neurochemical and neurophysiological alterations. Among the various 
synaptic and electrophysiological alterations described in these models, a major common 
characteristic seems to be abnormal corticostriatal synaptic plasticity. Early-onset primary DYT1 
dystonia (DYT1 dystonia), the most common and severe form of inherited dystonia, is caused by a 
3bp deletion on a glutamic acid residue in the C-terminal coding region of the protein torsinA31. In 
transgenic mice overexpressing mutant torsinA, no corticostriatal LTD could be elicited, whereas 
LTP was greater than in control animals. Moreover, while LFS reverted potentiated synapses to 
resting levels (depotentiation) in control mice, this phenomen form of homeostatic plasticity was 
absent in mutant mice (Figure 1B)32. Of note, these abnormalities in synaptic plasticity were 
reproducible across species and distinct mouse lines, as they were found both in transgenic rats 
overexpressing mutant torsinA33, as well as in knock-in mice heterozygous for Δ-torsinA 
(Tor1a+/Δgag)34. Collectively, these findings confirm the existence of a specific endophenotype 
linked to DYT1 mutation and indicate that the “loss of down-scaling” is a distinctive feature in 
multiple models of DYT1 dystonia. 
A major contributor to the aberrant control of synaptic plasticity in the DYT1 model appears to be a 
breakdown of the usual reciprocal relationship between striatal DA and acetylcholine35,36, due a 
change in D2 receptor (D2R)-regulation of cholinergic activity. Data collected from different mouse 
and rat rodent models of DYT1 dystonia show that the D2 receptor agonist quinpirole produces a 
paradoxical excitation of cholinergic interneurons, rather than inhibition37,38. The consequent 
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imbalance in neurotransmitter content impairs bidirectional corticostriatal synaptic plasticity, which 
can then be restored by anticholinergic drugs. This is consistent with the clinical use of 
anticholinergic agents in dystonia, and offers a rationale for the development of improved 
antimuscarinic therapies. Moreover, a relevant link has been demonstrated between torsinA 
mutation and D2 receptor: A2A receptor antagonism counteracts the deficit in D2 receptor deficit 
observed in mutant mice, suggesting that modulation of PKA is a critical pathophysiological factor 
(Figure 2)39. 
Targeting the intrinsic cholinergic system with Anticholinergic drugs reverses the deficit in motor 
control and restores striatal LTD in DYT1 ΔGAG knock-in heterozygous mice40. In a novel model, 
showing conditional deletion of torsinA in embryonic progenitors of forebrain cholinergic and 
GABAergic neurons it has been observed that the onset of dystonic movements correlates with 
degeneration of striatal cholinergic interneurons, while remaining interneurons show morphological 
and electrophysiological alterations. More importantly, abnormal movements were significantly 
reduced with an antimuscarinic drug41.  
It has been proposed that excessive plasticity, particularly in the developing motor system, could 
lead to the formation of extra connections between inputs and outputs that lead to expression of 
excessive muscular activity and unwanted movements of dystonia. This is exacerbated by the 
failure of depotentiation, which could normally be involved in reversing such changes, but which 
become permanent in dystonia. Altogether these findings taken together further support the 
hypothesis that impaired balance among glutamatergic inputs, cholinergic interneurons, responses 
to dopaminergic signal, and activity of SPNs are involved in the striatal motor abnormalities in 
DYT1 dystonia42.  
 
 9 
 
Synaptic dysfunctions in experimental models of L-DOPA-induced dyskinesia in Parkinson’s 
disease  
L-DOPA initially revolutionized the symptomatic treatment of PD43. Unfortunately, treatment 
becomes complicated in most patients after 5–10 years with increasingly frequent motor 
fluctuations and hyperkinetic involuntary movements9.  
It has been hypothesised that the development of LID is linked to impaired synaptic plasticity at 
corticostriatal synapses and in particular with the loss of synaptic depotentiation44. Indeed, DA-
denervation in rats using the toxin 6-hydroxy-dopamine (6-OHDA) causes loss of corticostriatal 
LTP that can be restored by chronic treatment with L-DOPA (Figure 1C)44. Interestingly, it has 
been demonstrated that depotentiation is selectively lost only in dyskinetic animals, whereas it is 
expressed in animals that do not develop involuntary movements (Figure 1C)44. This suggests that 
loss of synaptic depotentiation might destabilize neuronal circuits in the basal ganglia, resulting in 
dyskinesias.  
Abnormalities of synaptic plasticity in dyskinetic animals are related to changes in the 
D1/PKA/DARPP-32 signaling pathway that inhibit protein phosphatase (PP)-1 activity (Figure 2), a 
molecule that is involved in depotentiation at corticostriatal synapses. Activation of D1 receptors 
results in PKA-catalyzed phosphorylation of DARPP-32 on Thr34, which, in turn, converts 
DARPP-32 into a potent inhibitor of PP-1. Interestingly, dyskinetic animals express higher levels of 
Thr34-phosphorylated DARPP-32 than non-dyskinetic rats and drug-naïve controls44. Accordingly, 
striatal synaptic depotentiation is prevented by pretreatment with PP-1 and PP-2A inhibitors, D1-
like-receptor agonists, and adenylyl cyclase activators44.  
The Ras-extracellular signal-regulated kinase (Ras-ERK) pathway a signal transduction cascade 
involved in synaptic plasticity, controls synaptic activity in SPNs and represents a critical signaling 
pathway downstream of the D1 receptor45. Notably, a recent study has shown that the Ras-ERK 
pathway regulates both activity-dependent striatal LTP and synaptic depotentiation. Genetic 
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inactivation of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1), a neuronal activator of Ras 
proteins, causes loss of LTP in SPNs in the direct pathway without affecting LTP in the indirect 
pathway. Interestingly, characterization of LTP in 6-OHDA-lesioned animals showing LID after 
chronic L-DOPA treatment has shown a complex Ras-GRF1- and pathway-independent, 
involvement of ERK45.  
A possible way to reduce LID involves targeting striatal phosphodiesterases, which regulate 
intracellular levels of cGMP46. The phosphodiesterase inhibitors zaprinast and UK-343664 rescue 
the loss of LTD at corticostriatal synapses via a mechanism requiring the modulation of intracellular 
cGMP levels. Intrastriatal injection of these drugs is also associated with reduced LID, thus 
supporting the idea that targeting phosphodiesterases can ameliorate LID by facilitating the re-
emergence of striatal LTD46. Moreover, it has been recently shown a complex serotonergic 
regulation on striatal bidirectional synaptic plasticity underlying the antidyskinetic effect of 
serotonergic agonists47. 
The molecular mechanisms of LID have also been investigated using spike-timing dependent 
plasticity (STDP) at corticostriatal synapses in slices from 6-OHDA-lesioned mouse models of 
parkinsonism and LID, generated in BAC transgenic mice with eGFP labeling the direct or indirect 
output pathways48. In control mice, bidirectional synaptic plasticity (LTP, LTD and depotentiation) 
can be observed in both striatal output pathways. In parkinsonian mice both pathways exhibit only 
unidirectional plasticity, irrespective of stimulation paradigm. A symptomatic dose of L-DOPA 
restores bidirectional plasticity in both pathways to levels comparable with control animals. In 
animals with LID, treatment with L-DOPA leads to LTD in the indirect pathway, whereas only LTP 
can be induced in the direct pathway. Thus, this study confirms the concept that while normal motor 
control requires bidirectional plasticity of both striatal outputs, dyskinetic movements are caused by 
a switch from bidirectional to unidirectional plasticity. 
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Another recent study suggests that STDP in the PD state and in LID is cell-type specific. In fact, the 
intrinsic excitability and corticostriatal synaptic connectivity of SPNs of the indirect pathway are 
lower in PD models than in healthy condition. Conversely, these properties of SPNs in the direct 
pathway are enhanced in tissues from PD models and suppressed in LID models49.  
 
Transcranial magnetic stimulation (TMS) and dysfunctional plasticity in the cortex of 
patients with hyperkinetic disorders  
TMS is a non-invasive method of stimulating the brain in conscious humans. Because it is not 
possible to stimulate deep brain structures such as basal ganglia reliably, the target in most studies 
of hyperkinetic movement disorders has been the motor cortex. TMS has the advantage that the 
response is easily quantified by measuring the size of the movement it evokes in contralateral 
muscles. The choice of motor cortex is supported by the fact that (1) it shows early degenerative 
changes (e.g. in HD50); (2) it receives dopaminergic innervation that influences synaptic plasticity51; 
and (3) it is a primary output target of basal-ganglia-thalamo-cortical circuits. Thus, it might be 
expected to reflect some of the changes described in striatal connections. 
A number of common TMS methods have been used in hyperkinetic movement disorders to probe: 
1. the excitability of cortico-spinal connections (motor thresholds), 
2. GABAa cortical inhibition (SICI, short interval intracortical inhibition), 
3. GABAb inhibition (silent period), 
4. a cholinergic-sensitive form of inhibition (SAI, short latency afferent inhibition) 
5. the initial stages of synaptic plasticity leading to LTP and LTD (rTMS, repetitive TMS; 
TBS, theta burst stimulation; PAS, paired associative stimulation, a form of STDP) (for summary 
see52). 
The response to these methods varies considerably between individuals, so that none is diagnostic. 
However, group differences are reliable given sufficiently large sample sizes. 
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Huntington’s disease  
Initial work on HD focused on measures of excitability and inhibition in clinically manifesting 
individuals. They appeared to suggest that the excitability of GABAa systems (SICI method) were 
reduced53 whereas GABAb (silent period) seemed elevated54,55. However, later studies sometimes 
failed to replicate the findings56 suggesting that the effects are small, if present. One report found 
reduced cholinergic-sensitive inhibition (SAI), which was even present in preclinical cases but this 
has not been replicated56. 
The effects of HD on plasticity are clearer. Three studies using different forms of plasticity-probing 
methods (rTMS, TBS and PAS) have all reported a smaller response than normal57-59, which would 
be consistent with the idea that plasticity at cortical synapses is reduced. Notably, between them 
these methods probed both facilitatory (LTP-like) and inhibitory (LTD-like) effects, and occurred 
even in non-symptomatic carriers suggesting early cortical involvement in HD before the 
appearance of clinical signs59. 
Dystonia 
As in HD, initial studies concentrated on measures of cortical excitability and GABA function. The 
majority of studies reported reduced GABAa excitability (SICI) in many types of focal dystonia 
(e.g.60-62). As usual, the effects are probably smaller than in the initial reports63,64. Similarly GABAb 
(silent period) has also been found to be reduced in most reports60,65,66, but not always (e.g.67). Other 
forms of inhibition have also been reported as reduced in patients with dystonia, such as “surround 
inhibition” (suppression of excitability in uninvolved hand muscles when people try to produce a 
focal contraction of just one muscle68) and inhibition from premotor to motor cortex69. All these 
studies are compatible with the notion that disordered control of inhibitory systems in motor cortex 
might contribute to the excess muscle activity that is characteristic of dystonia. However, in patients 
with focal dystonia these changes can often be observed in clinically unaffected parts of the body; 
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they can also be seen in patients with “psychogenic” dystonia, suggesting that some other factor 
determines whether dystonia occurs. 
Building on the work in experimental animals, there have been a large number of studies of cortical 
plasticity in dystonia. Initial work70,71 found a pronounced increase in the responsiveness to tests of 
both LTP-like and LTD-like plasticity (PAS protocol). Although this has been replicated in several 
later studies (e.g.72-75), it is not a universal finding (e.g.76), probably because of the inter-individual 
variation in the effect size. Notably it is easier to demonstrate increased plasticity in patients with 
organic dystonia than in “psychogenic” cases, suggesting that it is an important contributor to 
clinical symptoms77. Finally, within individuals, there is reduced  homeostatic regulation control of 
plasticity in dystonia78,79. All of these changes have been regarded as consistent with the notion that 
excessive muscle contractions in dystonia arise because of formation of unwanted associations 
between activity in remote muscles and a prime mover. 
Parkinson’s disease and LID  
Most of the work examining differences between patients with and without dyskinesia has focused 
on measures of cortical plasticity. The initial study of Morgante et al80 found absent LTP-like 
plasticity (PAS protocol) in patients when off treatment that was restored after administration of L-
DOPA. Importantly, this effect was not seen in patients who had LID, consistent with a lack of 
dopaminergic modulation of synaptic plasticity in these cases. More recently, a TMS method for 
probing depotentiation of LTP-like plasticity has been introduced by Huang et al61. Consistent with 
the animal models, patients with LID were unresponsive to the depotentiation protocol (Figure 
3A)81 suggesting that depotentiation is abnormal in the motor cortex of patients with LID.  
 
Deep brain stimulation and aberrant plasticity in the basal ganglia of patients with 
hyperkinetic disorders 
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Deep brain stimulation (DBS), utilizing high-frequency electrical stimulation of deep brain 
structures, is an effective therapeutic option for treatment of a variety of neurological and 
psychiatric disorders82. DBS targeting the internal segment of the globus pallidus (GP), subthalamic 
nucleus (STN), and thalamus is used to treat symptoms of movement disorders, such as PD 
associated with LID and dystonia (Figure 4A).  
The first study that characterized synaptic plasticity in PD patients with DBS electrodes implanted 
in the STN measured field potentials (fEPs) in substantia nigra pars reticulata (SNr) that were 
evoked by stimulation through a nearby microelectrode83. HFS in the SNr failed to induce a lasting 
change in test fEPs in patients OFF medication whereas after oral L-DOPA administration, it 
potentiated fEP amplitudes, indicating that DA medication restores LTP-like changes in the human 
basal ganglia. In a more recent study, the same group has analyzed whether LFS in the GPi and SNr 
could depotentiate synapses that had already undergone HFS-induced potentiation84. GPi and SNr 
synapses in PD patients with less severe LID underwent greater depotentiation following LFS than 
in patients with more severe LID (Figure 4B). This demonstration of impaired depotentiation in 
basal ganglia output nuclei in PD patients with dyskinesia is an important validation of animal 
models of LID. Indeed, the ability of a synapse to reverse previous potentiation may be crucial to 
the normal function of the basal ganglia, avoiding storage of non-essential motor information.  
DBS of GPi is an excellent treatment for primary generalized or segmental dystonia. It is less 
effective for dystonia secondary to structural brain damage85. It has been hypothesized that DBS 
suppresses abnormally enhanced synchronized oscillatory activity within the motor cortico-basal 
ganglia network. Accordingly, pallidal DBS suppresses pathologically enhanced low frequency 
activity in patients with dystonia86.  
Electrophysiological features of dystonia in patients prior to and in the early treatment period 
following pallidal DBS have been assessed longitudinally87. Following DBS, short-latency 
intracortical inhibition increased toward normal levels with the same time course as the patients' 
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clinical benefit88. In contrast, synaptic plasticity changed rapidly, following a different time course. 
Clinical benefit may be delayed because engrams of abnormal movement persist and take time to 
normalize suggesting that plasticity may be a driver of long-term therapeutic effects of DBS in 
dystonia. 
The use of DBS in the treatment of HD is in an exploratory phase and the optimal brain structure to 
be targeted has to be determined. The number of patients treated with DBS for HD is small, 
however, preliminary studies show benefit following internal and external GP stimulation. The 
thalamus, STN, and substantia nigra pars compacta could also be potential targets. Further clinical 
studies are necessary to validate the efficacy of neuromodulation and to determine the optimal 
target for HD89.  
 
Abnormal excitability as a target for therapeutic interventions in hyperkinetic movement 
disorders  
In the last decade rTMS has been widely used as a possible treatment for both PD and hyperkinetic 
movement disorders. Although studies on the efficacy of rTMS in treating movement produced 
variable results, mostly owing to the variety in individual rTMS protocols, evidence suggests that 
rTMS improves motor symptoms for these patients. Combinations of rTMS site and frequency as 
well as the number of rTMS pulses are key modulators of rTMS effects90,91. Most of these studies 
have been focused on the treatment of PD with LID and on dystonia, while only a few reports have 
reported data on HD patients. In most of these therapeutic trials the driving hypothesis has been the 
attempt to restore the physiological bidirectional plasticity that in hyperkinetic disorders might be 
lost at cortical and subcortical levels.  
The most complete set of data is for rTMS treatment of PD where there have been more than one 
hundred studies. The results of the most robust of these trials are summarized in the review by 
Lefaucheur et al92. The consensus is that rTMS over M1, premotor or supplementary motor areas 
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may have some potential clinical benefit but that the effects so far reported are too small to be of 
useful in clinical practice. 
There has also been interest in using rTMS to reduce LID. Interestingly, rTMS at 1-Hz but not 5-Hz 
over the supplementary motor area (SMA) in a group of patients with advanced PD reduced 
dyskinesias induced by continuous apomorphine infusion (Figure 3B)93. This observation indicates 
that the most effective therapeutic protocol is similar to the one producing depotentiation in animal 
studies. The existence of residual beneficial clinical after effects of consecutive daily applications of 
low-frequency rTMS on LID in PD has been also demonstrated in a placebo-controlled, single-
blinded, crossover study94.  
Some studies have explored the possibility that LID can be reduced by targeting brain structures 
that are not included in the “classical” basal ganglia circuits. Continuous theta burst stimulation of 
the cerebellum may have anti-dyskinetic effects, possibly via the modulation of cerebello-
thalamocortical pathways95. A study combining resting state functional magnetic resonance imaging 
with rTMS has shown that the inferior frontal cortex is implicated in LID and could be a potential 
therapeutic target96.  
In dystonia, increased cortical excitability of the motor cortex and the brain stem97 could be a target 
for rTMS modulation. Again, the consensus at the present time92 from the small number of studies 
that have been completed is that any effects are small and at present are not of clinical relevance.  
There have been case studies reporting improvement in choreiform movements with administration 
of low-frequency rTMS lasting for a brief period rTMS98. However, other case series using bilateral 
low-frequency rTMS in patients with severe HD failed to replicate the findings99. 
 
Conclusions 
 17 
 
Both experimental and clinical findings suggest that in hyperkinetic disorders distinct but also 
common mechanisms interact at both cellular and network levels to influence synaptic scaling and 
synaptic plasticity.  
In physiological conditions, the compartmentalization of synaptic plasticity to specific connections 
and neuronal populations facilitates appropriate information storage of motor-related signals. In 
hyperkinetic disorders, the specificity of cellular and network related plasticity is lost, with the 
results that cortex and basal ganglia store non-essential redundant information. This loss of 
specificity in hyperkinetic disorders can occur at different levels and is linked to the genetic and/or 
molecular bases underlying the disease: (1) abnormalities of activity-dependent post-translational 
modifications of synaptic proteins at the activated synapses; (2) paradoxical local protein synthesis 
and degradation at synapses and (3) disruption of the molecular mechanisms contributing to 
depotentiation. 
Clinical electrophysiological studies using TMS and DBS (Figures 3 and 4) have confirmed the role 
of maladaptive plasticity in patients with hyperkinetic disorders. More importantly, clinician 
scientists have begun to use these methods are now commonly utilized to target this pathological 
plasticity and ameliorate some of the symptoms associated with these disorders. The challenge for 
the future will be to harness new techniques such as optogenetics to take advantage of existing 
promising results obtained in experimental animal models and apply them to patients with 
hyperkinetic movement disorders (Figure 5)100,101.  
At present, however, there is still a gap in the knowledge on the reciprocal links between plastic 
changes occurring in the basal ganglia and aberrant plasticity observed in the cortex. In fact, while 
most electrophysiological studies on animal models of hyperkinetic disorders focus on basal ganglia 
circuits, clinical electrophysiological studies using TMS mostly target cortical circuits (motor 
cortex). Although this gap should be filled in future studies, loss of down-scaling in both cortical 
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and subcortical structures might represent a common synaptic mechanism occurring in distinct 
hyperkinetic disorders, as detected using neurophysiological approaches (Figure 5). 
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Figure legends 
Figure 1. Alterations of striatal synaptic plasticity in three experimental models of hyperkinetic 
disorders. (A) The graph shows the time course of excitatory postsynaptic potential (EPSP) 
amplitude in response to high frequency stimulation (HFS) and subsequent low frequency 
stimulation (LFS), recorded in striatal spiny neurons from R6/2 mice (dark green), modelling 
Huntington’s disease (HD) and wild type controls (WT mice, light green) (modified from15). Note 
that LTP is equally expressed in both WT and HD mice while this latter group do not show 
depotentiation after LFS. (B) The graph shows the time course of EPSP responses to HFS and 
synaptic depotentiation protocol in a dystonia model, obtained through intracellular recordings 
carried in corticostriatal slices from transgenic mice overexpressing human mutant (hMT, dark red) 
and wild type TorsinA controls (hWT, orange) (modified from32). Note that the genetic model of 
dystonia shows an increased LTP and a loss of depotentiation in comparison with the controls. (C) 
The plot illustrates the changes in mean EPSP amplitudes following HFS and LFS in 6-OHDA-
lesioned rats chronically treated with L-DOPA. Animals responding to L-DOPA treatment with 
dyskinesia fail to display synaptic depotentiation following LFS (dark blue), while animals showing 
therapeutic effects of L-DOPA (light blue) display a full recovery of bidirectional synaptic 
plasticity (modified from44). On the right the electrophysiological traces represent examples of 
EPSP recorded in the various experimental conditions. Vertical and horizontal scale bars measure 
10 mV and 20 ms, respectively. 
 
Figure 2. Schematic representation of the common abnormalities in cAMP/PKA pathway 
downstream dopamine D1 and adenosine A2A receptors in striatal spiny neurons in experimental 
models of hyperkinetic disorders. Synaptic alterations in Huntington’s disease, dystonia and L-
DOPA-induced dyskinesia are associated with abnormal functioning of dopamine D1 and adenosine 
A2A receptors, expressed in striatonigral (D1-positive, left) and striatopallidal (D2-positive, right) 
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spiny neurons. Aberrant stimulation of D1 receptors induce abnormal activation of PKA and 
increased phosphorylation of DARPP-32, associated with reduction of protein phosphatase 1 action 
on NMDA receptors. A similar pattern of alteration is hypothesized downstream hyperactive A2A 
receptors. 
 
Figure 3. Effects of TMS on motor cortex plasticity in PD patients with L-DOPA-induced 
dyskinesia (LID). (A) Continuous theta burst stimulation (10 seconds train) followed by 1-min of 
voluntary contraction (cTBSc0) was used as protocol to induce LTP of motor evoked potentials 
(MEP). To depotentiate (Depo, dotted lines) this previously induced LTP a 10 seconds train of 
continuous TBS (cTBS150) was given at 1 min after cTBSc0. In healthy subjects (left) synaptic 
depotentiation is observed, while PD patients with LID, who had received a half dose of L-DOPA 
(right) were not able to show reversal of LTP following the application of the two protocols 
(modified from81). (B) The graph shows the time course of mean Abnormal Involuntary Movement 
Scale (AIMS) scores in PD patients with disabling LID before and after two different repetitive 
transcranial magnetic stimulation (rTMS) protocols. While 5-Hz protocol (blue dotted lines) failed 
to produce therapeutic benefit, low frequency 1-Hz stimulation (light blue continuous lines), 
mimicking the depotentiation protocol applied in experimental animal models, was able to decrease 
AIMS score in most of the patients (modified from93). 
 
Figure 4. Effects of deep brain stimulation (DBS) on subcortical synaptic plasticity in dystonic and 
PD patients with LID. (A) The graph shows paired pulse response curves of field potentials 
recorded in the substantia nigra pars reticulata (SNr) of PD patients (left) and dystonic subjects 
(right) before and after high frequency stimulation across a range of interstimulus intervals (ISI). In 
the SNr of PD patients on dopaminergic medication paired stimulation before HFS evoked a paired-
pulse depression (dark blue) that was further increased following HFS (light blue). Conversely, in 
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the SNr of dystonic patients, no measurable paired pulse depression was observed at any ISI before 
HFS (dark red). Following HFS in these patients, a paired pulse depression was observed (orange) 
(modified from88). (B) This diagram, showing the amplitude of field potentials recorded from SNr 
during DBS procedure, reveals the relationship between the response to LFS-induced change with 
the dyskinesia score. The selection of population by dyskinesia severity and duration reveals 2 
groups within the ON data; one group, with low level of dyskinesia that responded to LFS and 
underwent depotentiation (light blue), and one group, with high level of dyskinesia that did not 
respond to LFS and fails to show depotentiation (dark blue) (modified from84). 
 
Figure 5. Translating synaptic plasticity in humans from in vitro models.  Both stimulation of 
motor cortex by transcranial magnetic stimulation (TMS, upper left) and high-frequency activation 
of either subthalamic nucleus (STN) or globus pallidus (GPi) by deep brain stimulation (DBS, 
upper right) converge to subcortical regions to rewire the basal ganglia circuit. Such a 
rearrangement involves, at synaptic level, long-term changes of the efficiency of corticostriatal 
synapses (left inset). Following high-frequency stimulation (HFS) of cortical fibers, these synapses 
can exhibit either LTD or LTP and then synaptic depotentiation (SD).   
 
Figure 5. Schematic diagram of possible effects of cell-type specific optogenetic stimulation in the 
motor cortex. Expression of channelrhodopsin-2 (ChR2) in cortical pyramidal neurons might allow 
targeted activation of corticostriatal pathways and induction of postsynaptic down-scaling in striatal 
spiny neurons by low frequency stimulation (left). Selective expression of ChR2 in cortical 
GABAergic interneurons would generate, upon high frequency optical stimulation, a strong 
intracortical GABAergic inhibition that could reduce the glutamatergic excitatory inputs to striatal 
spiny neurons (right). Both these approaches could modulate the output signals from the striatum 
and ameliorate hyperkinetic movement disorders. 
